{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:07:35Z","timestamp":1770217655185,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T00:00:00Z","timestamp":1363046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/nrcardio.2013.28","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T11:38:19Z","timestamp":1363088299000},"page":"183-184","source":"Crossref","is-referenced-by-count":12,"title":["Optimal blockade of the renin\u2013angiotensin\u2013aldosterone system"],"prefix":"10.1038","volume":"10","author":[{"given":"J\u00fcrg","family":"Nussberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Bohlender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"BFnrcardio201328_CR1","doi-asserted-by":"publisher","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani, H., Bangalore, S., Desouza, K. A., Shah, A. & Messerli, F. H. Efficacy and safety of dual blockade of the renin\u2013angiotensin system: meta-analysis of randomised trials. BMJ 346, f360 (2013).","journal-title":"BMJ"},{"key":"BFnrcardio201328_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S Oparil","year":"2007","unstructured":"Oparil, S. et al. Efficacy and safety of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221\u2013229 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio201328_CR3","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","volume":"117","author":"ND Fisher","year":"2008","unstructured":"Fisher, N. D., Danser, A. H., Nussberger, J., Dole, W. P. & Hollenberg, N. K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117, 3199\u20133205 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio201328_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving, H. H. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433\u20132446 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201328_CR5","unstructured":"European Medicines Agency. European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines [online] , (2012)."},{"key":"BFnrcardio201328_CR6","doi-asserted-by":"publisher","unstructured":"Whitbeck, M. G. et al. Increased mortality among patients taking digoxin\u2014analysis from the AFFIRM study. Eur. Heart J. http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehs348 .","DOI":"10.1093\/eurheartj\/ehs348"},{"key":"BFnrcardio201328_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink, D. N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201328_CR8","doi-asserted-by":"crossref","first-page":"31334","DOI":"10.1016\/S0021-9258(18)31697-1","volume":"269","author":"K Tanimoto","year":"1994","unstructured":"Tanimoto, K. et al. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269, 31334\u201331337 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio201328_CR9","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","volume":"96","author":"J M\u00e9nard","year":"1997","unstructured":"M\u00e9nard, J., Campbell, D. J., Azizi, M. & Gonzales, M. F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96, 3072\u20133078 (1997).","journal-title":"Circulation"},{"key":"BFnrcardio201328_CR10","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.28","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2013.28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:52:38Z","timestamp":1684468358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2013.28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,12]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["BFnrcardio201328"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2013.28","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,12]]}}}